{"id":745313,"date":"2016-10-24T17:04:00","date_gmt":"2016-10-24T17:04:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\/"},"modified":"2025-11-07T01:25:35","modified_gmt":"2025-11-07T06:25:35","slug":"fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\/","title":{"rendered":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations"},"content":{"rendered":"<p class=\"bwalignc\">       KEYTRUDA is the Only Anti-PD-1 Therapy Approved in First-Line        Treatment of Metastatic NSCLC; KEYTRUDA Demonstrated Superior        Progression-Free and Overall Survival Compared to Chemotherapy in        Patients Whose Tumors Expressed High Levels of PD-L1     <\/p>\n<p class=\"bwalignc\">       FDA Also Approves a Labeling Update for KEYTRUDA for the Treatment of        Patients with Metastatic NSCLC Whose Tumors Express PD-L1 (TPS of One        Percent or More) With Disease Progression On or After        Platinum-Containing Chemotherapy; Patients With EGFR or ALK Genomic        Tumor Aberrations Should Have Disease Progression On FDA-Approved        Therapy for These Aberrations Prior to Receiving KEYTRUDA     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      approved KEYTRUDA<sup>\u00ae <\/sup>(pembrolizumab), the company\u2019s anti-PD-1<br \/>\n      (programmed death receptor-1) therapy, for the first-line treatment of<br \/>\n      patients with metastatic non-small cell lung cancer (NSCLC) whose tumors<br \/>\n      have high PD-L1 expression (tumor proportion score [TPS] of 50 percent<br \/>\n      or more) as determined by an FDA-approved test, with no EGFR or ALK<br \/>\n      genomic tumor aberrations. With this new indication, KEYTRUDA is now the<br \/>\n      only anti-PD-1 therapy to be approved in the first-line treatment<br \/>\n      setting for these patients. In addition, the FDA approved a labeling<br \/>\n      update to include data from KEYNOTE-010 in the second-line or greater<br \/>\n      treatment setting for patients with metastatic NSCLC whose tumors<br \/>\n      express PD-L1 (TPS of one percent or more) as determined by an<br \/>\n      FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA. In metastatic<br \/>\n      NSCLC, KEYTRUDA is approved for use at a fixed dose of 200 mg every<br \/>\n      three weeks until disease progression, unacceptable toxicity, or up to<br \/>\n      24 months in patients without disease progression.\n    <\/p>\n<p>\n      Immune-mediated adverse reactions occurred with KEYTRUDA including<br \/>\n      pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis. Based<br \/>\n      on the severity of the adverse reaction, KEYTRUDA (pembrolizumab) should<br \/>\n      be withheld or discontinued and corticosteroids administered when<br \/>\n      appropriate. KEYTRUDA can also cause severe or life-threatening<br \/>\n      infusion-related reactions. Monitor patients for signs and symptoms of<br \/>\n      infusion-related reactions and for Grade 3 or 4 reactions, stop infusion<br \/>\n      and permanently discontinue KEYTRUDA. Based on its mechanism of action,<br \/>\n      KEYTRUDA can cause fetal harm when administered to a pregnant woman.<br \/>\n      Female patients of reproductive potential should be advised of the<br \/>\n      potential hazard to a fetus. For more information regarding<br \/>\n      immune-mediated and infusion-related adverse reactions and use in<br \/>\n      pregnancy, see \u201cSelected Important Safety Information\u201d below.\n    <\/p>\n<p>\n      \u201cKEYTRUDA improved survival, compared to traditional chemotherapy, in<br \/>\n      patients with non-small cell lung cancer whose tumors express high<br \/>\n      levels of PD-L1,\u201d said Roger M. Perlmutter, M.D., Ph.D., president,<br \/>\n      Merck Research Laboratories. \u201cThe approval of KEYTRUDA for the<br \/>\n      first-line treatment of metastatic non-small cell lung cancer has the<br \/>\n      potential to change the treatment landscape for these patients.\u201d\n    <\/p>\n<p>\n      \u201cWith this new indication, KEYTRUDA can now be a first treatment option<br \/>\n      instead of chemotherapy for patients with metastatic non-small cell lung<br \/>\n      cancer whose tumors express high levels of PD-L1,\u201d said Roy S. Herbst,<br \/>\n      M.D., Ph.D., professor of medicine and chief of medical oncology, Yale<br \/>\n      Cancer Center and Smilow Cancer Hospital at Yale New Haven. \u201cThese data<br \/>\n      reaffirm the importance of testing for PD-L1 expression in non-small<br \/>\n      cell lung cancer in order to identify those patients who are most likely<br \/>\n      to benefit from treatment with KEYTRUDA.\u201d\n    <\/p>\n<p>\n      <b>Data Supporting First-Line Approval<\/b>\n    <\/p>\n<p>\n      The approval was based on data from KEYNOTE-024, a randomized,<br \/>\n      open-label, phase 3 study evaluating KEYTRUDA monotherapy compared to<br \/>\n      standard of care (SOC) platinum-containing chemotherapy for the<br \/>\n      treatment of patients with both squamous (18%) and non-squamous (82%)<br \/>\n      metastatic NSCLC. The study enrolled patients who had not received prior<br \/>\n      systemic chemotherapy treatment for their metastatic disease and whose<br \/>\n      tumors had high PD-L1 expression (TPS of 50 percent or more) and with no<br \/>\n      EGFR or ALK aberrations. The study randomized 305 patients to receive<br \/>\n      KEYTRUDA (200 mg every three weeks) or investigator-choice SOC<br \/>\n      platinum-based chemotherapy (pemetrexed+carboplatin,<br \/>\n      pemetrexed+cisplatin, gemcitabine+cisplatin, gemcitabine+carboplatin, or<br \/>\n      paclitaxel+carboplatin). Pemetrexed maintenance therapy was permitted<br \/>\n      for patients with non-squamous histologies. The primary endpoint was<br \/>\n      progression-free survival (PFS); additional efficacy outcome measures<br \/>\n      were overall survival (OS) and overall response rate (ORR).\n    <\/p>\n<p>\n      Based on an interim analysis demonstrating KEYTRUDA (pembrolizumab) was<br \/>\n      superior compared to chemotherapy for both the primary endpoint of PFS<br \/>\n      and the secondary endpoint of OS, the trial was stopped early in June<br \/>\n      2016 to give patients still on chemotherapy the opportunity to receive<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Findings demonstrated that KEYTRUDA reduced the risk of progression or<br \/>\n      death by 50 percent compared to chemotherapy (HR, 0.50 [95% CI, 0.37,<br \/>\n      0.68]; p&lt;0.001). Additionally, KEYTRUDA resulted in a 40 percent<br \/>\n      reduction in the risk of death compared to chemotherapy (HR, 0.60 [95%<br \/>\n      CI, 0.41, 0.89]; p=0.005).\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Efficacy Results from KEYNOTE-024\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>Endpoint<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>KEYTRUDA <\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>200 mg every 3 weeks <\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>(n=154)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>Chemotherapy <\/b><\/p>\n<p class=\"bwcellpmargin\">&nbsp;<\/p>\n<p class=\"bwcellpmargin\">\n            <b>(n=151)<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>PFS<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Number (%) of patients with event\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          73 (47%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          116 (77%)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Median in months (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          10.3 (6.7, NR)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          6.0 (4.2, 6.2)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Hazard ratio* (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"3\">\n          0.50 (0.37, 0.68)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          p-Value (stratified log-rank)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"3\">\n          &lt;0.001\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>OS<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Number (%) of patients with event\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          44 (29%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          64 (42%)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Median in months (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          NR<\/p>\n<p class=\"bwcellpmargin\">\n            (NR, NR)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          NR<\/p>\n<p class=\"bwcellpmargin\">\n            (9.4, NR)\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Hazard ratio* (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"3\">\n          0.60 (0.41, 0.89)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          p-Value (stratified log-rank)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"3\">\n          0.005<sup>\u2020<\/sup>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>Objective Response Rate<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          ORR % (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          45% (37, 53)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          28% (21, 36)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl7  bwvertalignt bwalignl bwsinglebottom\">\n          Complete response %\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          4%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl7  bwvertalignt bwalignl bwsinglebottom\">\n          Partial response %\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          41%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          27%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          p-Value (Miettenen-Nurminen)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"3\">\n          0.001\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Median duration of response<br \/>in months (range)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            NR<br \/>(1.9+, 14.5+)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            6.3<br \/>(2.1+, 12.6+)\n          <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          * Based on the stratified Cox proportional hazard model\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          <sup>\u2020 <\/sup>P-value is compared with 0.0118 of the allocated alpha<br \/>\n          for this interim analysis\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          NR = not reached\n        <\/td>\n<\/tr>\n<tr>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      \u201cThe approval of KEYTRUDA in the first-line setting adds to the momentum<br \/>\n      of progress that has been made to treat lung cancer, particularly in the<br \/>\n      area of immunotherapy,\u201d said Laurie Fenton Ambrose, president and CEO,<br \/>\n      Lung Cancer Alliance. \u201cPatients now have an option beyond chemotherapy<br \/>\n      at initial diagnosis. This approval reinforces the need for biomarker<br \/>\n      testing so care can be personalized and most effective.\u201d\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis. See additional \u201cSelected Important Safety Information\u201d<br \/>\n      below.\n    <\/p>\n<p>\n      <b>Data Supporting Second-Line Labeling Update<\/b>\n    <\/p>\n<p>\n      KEYNOTE-010 is a randomized, open-label, phase 2\/3 trial evaluating<br \/>\n      KEYTRUDA (2 mg\/kg [n=344] or 10 mg\/kg [n=346] every three weeks)<br \/>\n      compared to SOC chemotherapy (docetaxel, 75 mg\/m<sup>2<\/sup> every three<br \/>\n      weeks [n=343]) in 1,033 patients with squamous (21%) and non-squamous<br \/>\n      (70%) metastatic NSCLC with all levels of PD-L1 expression (TPS of one<br \/>\n      percent or more) who had progressed following platinum-containing<br \/>\n      chemotherapy and, if appropriate, targeted therapy for EGFR or ALK<br \/>\n      genomic tumor aberrations. Additionally, results were reported in a<br \/>\n      subset of patients who had high PD-L1 expression (TPS of 50 percent or<br \/>\n      more) in the KEYTRUDA 2 mg\/kg (n=139), KEYTRUDA 10 mg\/kg (n=151), and<br \/>\n      chemotherapy cohorts (n=152). The primary endpoints were OS and PFS.<br \/>\n      Additional efficacy measures included ORR and response duration.\n    <\/p>\n<p>\n      KEYTRUDA demonstrated superior OS versus docetaxel in patients with all<br \/>\n      levels of PD-L1 expression.&nbsp;Based on exploratory analyses, higher OS was<br \/>\n      associated with higher PD-L1 expression level.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"7\">\n<p class=\"bwcellpmargin\">\n            Efficacy Results from KEYNOTE-010: Subgroup of Patients with TPS<br \/>\n            of 50 Percent or More\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>Endpoint<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>KEYTRUDA <\/b><br \/>\n<br \/>\n<b>2 mg\/kg every <\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>3 weeks<\/b><br \/>\n<br \/>\n<b>n=139<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>KEYTRUDA <\/b><br \/>\n<br \/>\n<b>10 mg\/kg every <\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>3 weeks<\/b><br \/>\n<br \/>\n<b>n=151<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>Docetaxel <\/b><br \/>\n<br \/>\n<b>75 mg\/m<\/b><br \/>\n<sup><br \/>\n<b>2<\/b><br \/>\n<\/sup><br \/>\n<b> every <\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>3 weeks<\/b><br \/>\n<br \/>\n<b>n=152<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>OS<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Deaths (%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          58 (42%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          60 (40%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          86 (57%)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Median in months (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          14.9 (10.4, NR)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          17.3 (11.8, NR)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          8.2 (6.4, 10.7)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Hazard ratio* (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.54 (0.38, 0.77)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.50 (0.36, 0.70)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          &#8212;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          p-Value (stratified log-rank)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          &lt;0.001\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          &lt;0.001\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          &#8212;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>PFS<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Events (%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          89 (64%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          97 (64%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          118 (78%)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Median in months (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          5.2 (4.0, 6.5)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          5.2 (4.1, 8.1)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          4.1 (3.6, 4.3)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Hazard ratio* (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.58 (0.43, 0.77)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.59 (0.45, 0.78)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          &#8212;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          p-Value (stratified log-rank)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          &lt;0.001\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          &lt;0.001\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          &#8212;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>Objective Response Rate<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl bwsinglebottom\">\n          ORR<sup>\u2020 <\/sup>(95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          30% (23, 39)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          29% (22, 37)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          8% (4, 13)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          p-Value (Miettenen-Nurminen)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          &lt;0.001\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          &lt;0.001\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          &#8212;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Median duration of response in<br \/>months (range)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          NR<br \/>(0.7+, 16.8+)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          NR<br \/>(2.1+, 17.8+)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          8.1<\/p>\n<p class=\"bwcellpmargin\">\n            (2.1+, 8.8+)\n          <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          * Hazard ratio (KEYTRUDA compared to docetaxel) based on the<br \/>\n          stratified Cox proportional hazard model\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          <sup>\u2020 <\/sup>All responses were partial responses\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          NR = not reached\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td colspan=\"7\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"7\">\n<p class=\"bwcellpmargin\">\n            Efficacy Results from KEYNOTE-010: All Randomized Patients with<br \/>\n            TPS of One Percent or More\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>Endpoint<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>KEYTRUDA <\/b><br \/>\n<br \/>\n<b>2 mg\/kg every <\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>3 weeks<\/b><br \/>\n<br \/>\n<b>n=344<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>KEYTRUDA <\/b><br \/>\n<br \/>\n<b>10 mg\/kg every <\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>3 weeks<\/b><br \/>\n<br \/>\n<b>n=346<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>Docetaxel <\/b><br \/>\n<br \/>\n<b>75 mg\/m<\/b><br \/>\n<sup><br \/>\n<b>2<\/b><br \/>\n<\/sup><br \/>\n<b> every <\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>3 weeks<\/b><br \/>\n<br \/>\n<b>n=343<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>OS<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Deaths (%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          172 (50%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          156 (45%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          193 (56%)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Median in months (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          10.4 (9.4, 11.9)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          12.7 (10.0, 17.3)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          8.5 (7.5, 9.8)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Hazard ratio* (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.71 (0.58, 0.88)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.61 (0.49, 0.75)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          &#8212;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          p-Value (stratified log-rank)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          &lt;0.001\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          &lt;0.001\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          &#8212;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>PFS<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Events (%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          266 (77%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          255 (74%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          257 (75%)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Median in months (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          3.9 (3.1, 4.1)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          4.0 (2.6, 4.3)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          4.0 (3.1, 4.2)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Hazard ratio* (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.88 (0.73, 1.04)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.79 (0.66, 0.94)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          &#8212;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          p-Value (stratified log-rank)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.068\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.005\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          &#8212;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>Objective Response Rate<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl bwsinglebottom\">\n          ORR<sup>\u2020 <\/sup>(95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          18% (14, 23)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          19% (15, 23)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          9% (7, 13)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          p-Value (Miettenen-Nurminen)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          &lt;0.001\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          &lt;0.001\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          &#8212;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Median duration of response in<br \/>months (range)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          NR<br \/>(0.7+, 20.1+)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          NR<br \/>(2.1+, 17.8+)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          6.2<\/p>\n<p class=\"bwcellpmargin\">\n            (1.4+, 8.8+)\n          <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          * Hazard ratio (KEYTRUDA compared to docetaxel) based on the<br \/>\n          stratified Cox proportional hazard model\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          <sup>\u2020 <\/sup>All responses were partial responses\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          NR = not reached\n        <\/td>\n<\/tr>\n<tr>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      In KEYNOTE-010, treatment was discontinued for adverse reactions in<br \/>\n      eight percent of the 682 patients receiving KEYTRUDA (pembrolizumab)<br \/>\n      across both doses. The most common adverse event resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.8%). Adverse reactions<br \/>\n      leading to interruption of KEYTRUDA (pembrolizumab) occurred in 23% of<br \/>\n      patients; the most common (\u22651%) were diarrhea (1%), fatigue (1.3%),<br \/>\n      pneumonia (1%), liver enzyme elevation (1.2%), decreased appetite<br \/>\n      (1.3%), and pneumonitis (1%). The most frequent adverse reactions<br \/>\n      (reported in at least 10% of KEYTRUDA patients and occurring at the same<br \/>\n      or higher incidence than in the docetaxel arm) were decreased appetite<br \/>\n      (25% for KEYTRUDA vs. 23% for docetaxel), dyspnea (23% vs. 20%), nausea<br \/>\n      (20% vs. 18%), cough (19% vs. 14%), rash (17% vs. 8%), constipation (15%<br \/>\n      vs. 12%), vomiting (13% vs. 10%), arthralgia (11% vs. 9%), back pain<br \/>\n      (11% vs. 8%), and pruritus (11% vs. 3%). Other clinically important<br \/>\n      adverse reactions occurring in patients receiving KEYTRUDA were fatigue<br \/>\n      (25%), diarrhea (14%), asthenia (11%), and pyrexia (11%).\n    <\/p>\n<p>\n      <b>PD-L1 Companion Diagnostic for Patients with Metastatic NSCLC<\/b>\n    <\/p>\n<p>\n      The PD-L1 IHC 22C3 PharmDx\u2122 kit made by Dako North America, Inc., an<br \/>\n      Agilent Technologies Company, was approved in 2015 by the FDA for use in<br \/>\n      detecting PD-L1, an immune-related biomarker expressed on some tumor<br \/>\n      cells. The diagnostic is intended to aid in identifying appropriate<br \/>\n      patients for treatment with KEYTRUDA, including previously treated<br \/>\n      patients whose tumors have any level of PD-L1 expression (TPS of one<br \/>\n      percent or more) and previously untreated patients whose tumors have<br \/>\n      high levels of PD-L1 expression (TPS of 50 percent or more). Tumors with<br \/>\n      a TPS of less than one percent are considered to have no PD-L1<br \/>\n      expression.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single use vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a dose of 2 mg\/kg every three weeks until disease<br \/>\n      progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is indicated for the first-line treatment of<br \/>\n      patients with metastatic NSCLC whose tumors have high PD-L1 expression<br \/>\n      (TPS \u226550%) as determined by an FDA-approved test, with no EGFR or ALK<br \/>\n      genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with metastatic<br \/>\n      NSCLC whose tumors express PD-L1 (TPS \u22651%) as determined by an<br \/>\n      FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy at a fixed dose<br \/>\n      of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.<br \/>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<br \/>\n      (continued)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA (pembrolizumab), including Grade 2 (6.2%)<br \/>\n      and 3 (0.1%) hypothyroidism. Thyroiditis occurred in 16 (0.6%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (0.3%) thyroiditis.<br \/>\n      Monitor patients for changes in thyroid function (at the start of<br \/>\n      treatment, periodically during treatment, and as indicated based on<br \/>\n      clinical evaluation) and for clinical signs and symptoms of thyroid<br \/>\n      disorders. Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer anti-hyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. For suspected immune-mediated adverse reactions, ensure<br \/>\n      adequate evaluation to confirm etiology or exclude other causes. Based<br \/>\n      on the severity of the adverse reaction, withhold KEYTRUDA and<br \/>\n      administer corticosteroids. Upon improvement to Grade 1 or less,<br \/>\n      initiate corticosteroid taper and continue to taper over at least 1<br \/>\n      month. Based on limited data from clinical studies in patients whose<br \/>\n      immune-related adverse reactions could not be controlled with<br \/>\n      corticosteroid use, administration of other systemic immunosuppressants<br \/>\n      can be considered. Resume KEYTRUDA when the adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), exfoliative dermatitis, bullous pemphigoid, rash<br \/>\n      (1.4%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis,<br \/>\n      vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising<br \/>\n      in a patient with inflammatory foci in brain parenchyma.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related reactions<br \/>\n      which have been reported in 6 (0.2%) of 2799 patients. Monitor patients<br \/>\n      for signs and symptoms of infusion-related reactions including rigors,<br \/>\n      chills, wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and<br \/>\n      fever. For Grade 3 or 4 reactions, stop infusion and permanently<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA (pembrolizumab) can cause<br \/>\n      fetal harm when administered to a pregnant woman. If used during<br \/>\n      pregnancy, or if the patient becomes pregnant during treatment, apprise<br \/>\n      the patient of the potential hazard to a fetus. Advise females of<br \/>\n      reproductive potential to use highly effective contraception during<br \/>\n      treatment and for 4 months after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 8% of 682 patients<br \/>\n      with metastatic NSCLC. The most common adverse event resulting in<br \/>\n      permanent discontinuation of KEYTRUDA was pneumonitis (1.8%). Adverse<br \/>\n      reactions leading to interruption of KEYTRUDA occurred in 23% of<br \/>\n      patients; the most common (\u22651%) were diarrhea (1%), fatigue (1.3%),<br \/>\n      pneumonia (1%), liver enzyme elevation (1.2%), decreased appetite<br \/>\n      (1.3%), and pneumonitis (1%). The most common adverse reactions<br \/>\n      (occurring in at least 20% of patients and at a higher incidence than<br \/>\n      docetaxel) were decreased appetite (25% vs. 23%), dyspnea (23% vs. 20%),<br \/>\n      and nausea (20% vs. 18%).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 360 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51445091&amp;newsitemid=20161024006572&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=70727301fde666fb9a678ed204e462fe\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51445091&amp;newsitemid=20161024006572&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=c2faae205b3c21b64ec1243ff11497a7\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51445091&amp;newsitemid=20161024006572&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=ce36d86b1c703d843f9e00377e0e3225\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51445091&amp;newsitemid=20161024006572&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=00c3a9a10ef91a7f5132ae02c5af400f\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51445091&amp;newsitemid=20161024006572&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=de774d874a24cebe94d6fae93dc6f64d\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51445091&amp;newsitemid=20161024006572&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=0ea8f9edd3d8e6b3fa75e7c4bea45337\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51445091&amp;newsitemid=20161024006572&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=5ce176184bf4c9ac70c0699f2e896301\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51445091&amp;newsitemid=20161024006572&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=d212ab529306e7aabe245e7543f4eae6\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51445091&amp;newsitemid=20161024006572&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=18eb714d0c278454932aac01cbc846af\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20161024006572r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Courtney        Ronaldo, 908-236-1108<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>KEYTRUDA is the Only Anti-PD-1 Therapy Approved in First-Line Treatment of Metastatic NSCLC; KEYTRUDA Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Expressed High Levels of PD-L1 FDA Also Approves a Labeling Update for KEYTRUDA for the Treatment of Patients with Metastatic NSCLC Whose Tumors Express PD-L1 (TPS of One Percent or More) With Disease Progression On or After Platinum-Containing Chemotherapy; Patients With EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression On FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 (programmed death receptor-1) therapy, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-745313","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations - Merck.com\" \/>\n<meta property=\"og:description\" content=\"KEYTRUDA is the Only Anti-PD-1 Therapy Approved in First-Line Treatment of Metastatic NSCLC; KEYTRUDA Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Expressed High Levels of PD-L1 FDA Also Approves a Labeling Update for KEYTRUDA for the Treatment of Patients with Metastatic NSCLC Whose Tumors Express PD-L1 (TPS of One Percent or More) With Disease Progression On or After Platinum-Containing Chemotherapy; Patients With EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression On FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 (programmed death receptor-1) therapy, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\\\/\",\"name\":\"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-10-24T17:04:00+00:00\",\"dateModified\":\"2025-11-07T06:25:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\/","og_locale":"en_US","og_type":"article","og_title":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations - Merck.com","og_description":"KEYTRUDA is the Only Anti-PD-1 Therapy Approved in First-Line Treatment of Metastatic NSCLC; KEYTRUDA Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Expressed High Levels of PD-L1 FDA Also Approves a Labeling Update for KEYTRUDA for the Treatment of Patients with Metastatic NSCLC Whose Tumors Express PD-L1 (TPS of One Percent or More) With Disease Progression On or After Platinum-Containing Chemotherapy; Patients With EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression On FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 (programmed death receptor-1) therapy, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:35+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\/","name":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-10-24T17:04:00+00:00","dateModified":"2025-11-07T06:25:35+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumors-have-high-pd-l1-expression-tumor-proportion-score-tps-of-50-percent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"fcded132-f981-433d-89e4-ce463d4210a3","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-in-Metastatic-NSCLC-for-First-Line-Treatment-of-Patients-Whose-Tumors-Have-High-PD-L1-Expr-AOEKY.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745313\/revisions"}],"predecessor-version":[{"id":3674720,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745313\/revisions\/3674720"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745313"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}